Nicotinic alpha-7 receptor ligands and preparation and uses...

Details Nicotinic alpha-7 receptor ligands and preparation and uses... Nicotinic alpha-7 receptor ligands and preparation and uses...

2005-12-21

2009-12-01

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S302000, C514S303000, C546S114000, C546S115000, C546S117000

Reexamination Certificate

active

07625924

ABSTRACT:
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

REFERENCES:
patent: 4605652 (1986-08-01), Welstead et al.
patent: 4775668 (1988-10-01), Jefson
patent: 4789673 (1988-12-01), Donatsch et al.
patent: 4798829 (1989-01-01), King et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4853376 (1989-08-01), King
patent: 4886808 (1989-12-01), King
patent: 4895943 (1990-01-01), Friedmann
patent: 4910193 (1990-03-01), Buchheit
patent: 4910207 (1990-03-01), Donatsch et al.
patent: 4937247 (1990-06-01), King
patent: 4942160 (1990-07-01), Sanger et al.
patent: 4975436 (1990-12-01), Tyers
patent: 4985424 (1991-01-01), van Wijngaarden et al.
patent: 5017582 (1991-05-01), Donatsch et al.
patent: 5034398 (1991-07-01), King
patent: 5063231 (1991-11-01), Sanger et al.
patent: 5098889 (1992-03-01), Costall et al.
patent: 5098909 (1992-03-01), Williams
patent: 5192770 (1993-03-01), Clark et al.
patent: 5204356 (1993-04-01), Tyers
patent: 5223625 (1993-06-01), van Wijngaarden et al.
patent: 5272154 (1993-12-01), Dixon et al.
patent: 5273972 (1993-12-01), Jagdmann et al.
patent: 5446050 (1995-08-01), Rosen
patent: 5543426 (1996-08-01), Dixon et al.
patent: 5561149 (1996-10-01), Azria et al.
patent: 5641802 (1997-06-01), Arcamone et al.
patent: 5679673 (1997-10-01), Brown et al.
patent: 5773436 (1998-06-01), Muller et al.
patent: 5985866 (1999-11-01), Muller et al.
patent: 6492385 (2002-12-01), Myers et al.
patent: 6500840 (2002-12-01), Myers et al.
patent: 6599916 (2003-07-01), Myers et al.
patent: 6624173 (2003-09-01), Crooks et al.
patent: 6780861 (2004-08-01), Nozulak
patent: 6828330 (2004-12-01), Walker et al.
patent: 6849620 (2005-02-01), Walker et al.
patent: 6911543 (2005-06-01), Walker et al.
patent: 7001900 (2006-02-01), Jacobsen et al.
patent: 2002/0086871 (2002-07-01), O'Neill et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2003/0073707 (2003-04-01), Walker et al.
patent: 2004/0002513 (2004-01-01), Mazurov et al.
patent: 2005/0182062 (2005-08-01), Galli et al.
patent: 2005/0209236 (2005-09-01), Luithle et al.
patent: 2005/0234095 (2005-10-01), Xie et al.
patent: 2006/0014750 (2006-01-01), O'Donnell et al.
patent: 2 361 437 (1988-03-01), None
patent: 101 56 719 (2003-05-01), None
patent: 103 05 922 (2004-03-01), None
patent: 0 013 138 (1980-07-01), None
patent: 0 200 444 (1986-11-01), None
patent: 0 214 772 (1987-03-01), None
patent: 0 279 512 (1988-08-01), None
patent: 0 377 238 (1990-07-01), None
patent: 0 498 466 (1992-08-01), None
patent: 1 079 828 (2001-03-01), None
patent: 1 219 622 (2002-07-01), None
patent: 1 235 826 (2002-09-01), None
patent: 0 261 964 (2008-08-01), None
patent: 2 548 666 (1985-01-01), None
patent: 2 125 398 (1984-03-01), None
patent: 2 145 416 (1985-03-01), None
patent: 2002-30084 (2002-01-01), None
patent: WO 84/00166 (1984-01-01), None
patent: WO 85/01048 (1985-03-01), None
patent: WO 90/14347 (1990-11-01), None
patent: WO 91/09593 (1991-07-01), None
patent: WO 92/12149 (1992-07-01), None
patent: WO 93/08185 (1993-04-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 00/45846 (2000-08-01), None
patent: WO 00/58311 (2000-10-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 01/90109 (2001-11-01), None
patent: WO 01 92260 (2001-12-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 02 36114 (2002-05-01), None
patent: WO 02/085901 (2002-10-01), None
patent: WO 02/096911 (2002-12-01), None
patent: WO 02/100833 (2002-12-01), None
patent: WO 02/100857 (2002-12-01), None
patent: WO 02/100858 (2002-12-01), None
patent: WO 03/022856 (2003-03-01), None
patent: WO 03 029252 (2003-04-01), None
patent: WO 03 037896 (2003-05-01), None
patent: WO 03/042210 (2003-05-01), None
patent: WO 03/051874 (2003-06-01), None
patent: WO 03/070731 (2003-08-01), None
patent: WO 03/072578 (2003-09-01), None
patent: WO 03/078431 (2003-09-01), None
patent: WO 03 080606 (2003-10-01), None
patent: WO 03/094830 (2003-11-01), None
patent: WO 03/101987 (2003-11-01), None
patent: WO 2004/014864 (2004-02-01), None
patent: WO 2004/014922 (2004-02-01), None
patent: WO 2004/016616 (2004-02-01), None
patent: WO 2004/016617 (2004-02-01), None
patent: WO 2004/029050 (2004-04-01), None
patent: WO 2004/033456 (2004-04-01), None
patent: WO 2005/001299 (2005-02-01), None
patent: WO 2005/012299 (2005-02-01), None
Dineley et al., the Journal of Biological Chemistry, 2002, vol. 277, pp. 22768-22780.
S.M. Evans et al., “Probing the 5-HT3Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives”, Med. Chem. Res. (1993), 3:386-406.
Bermudez et al., J. Med. Chem. 1990. 33, 1924-1929.
D. Flammia, “Lobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding”, J. Med. Chem. (1999), 42:3726-2731.
R. Azuma et al. “Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease”, Xenobiotica (1999). vol. 29, No. 7, pp. 747-762.
K. E. Stevens. Et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice”, Psychopharmacology (1998), 136:320-327.
R. Azuma et al., “The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat”, Elsevier Science Ireland Ltd., Toxicology Letters 110 (1999) pp. 137-144.
M. Decker, et al., “Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics”, pp. 1-14.
M. W. Holladay et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery”, Journal of Medicinal Chemistry, vol. 40, No. 26, (1997), pp. 4169-4194.
Astles et al., Current Drug Targets—CNS Neurological Disorders, 2002, 1, pp. 337-348.
Mazurov et al., Biorg. & Med. Chem. Lett., 2005, No. 1 15, pp. 2073-2077.
Nurhrich et al., Eur. J. Med. Chem. 1996, No. 31, pp. 957-964.
Partial International Search Report issued May 16, 2006 in PCT/US2005/046256.
R. Tatsumi, et al., “(+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2] . . . ”, Bioorganic & Medicinal Chemistry Letters, vol. 14, (2004), pp. 3781-3784.
J.E. Macor, et al., “The 5-HT3Antagonist Tropisetron (ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist”, Bioorganic & Medicinal Chemistry Letters, vol. 11, (2001), pp. 319-321.
International Search Report issued Aug. 11, 2006 in PCT/US2005/046256.
John E. Macor, et al. “The 5-HT3Antagonist Tropisetron (ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist”, Bioorganic & Medicinal Chemistry Letters 11, (2001) pp. 319-321.
Ryo Tatsumi, et al., “(+)-3-[12-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2] . . . ”, Bioorganic & Medicinal Chemistry Letters 14 (2004) pp. 3781-3784.

Affiliated with

Also associated with

Rating

Nicotinic alpha-7 receptor ligands and preparation and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nicotinic alpha-7 receptor ligands and preparation and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinic alpha-7 receptor ligands and preparation and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4149700